top of page
How Precision Medicine is Changing Treatment
March 2025 | IVPMED
Nanoparticle Delivery: Enabling the Next Generation of Precision Treatments
IVPMED’s nanoparticle delivery system represents a leap forward in how pharmaceuticals are formulated and administered. By reducing active pharmaceutical ingredients to the nanometer scale, our technology enhances bioavailability, absorption, and targeting precision — all without altering the molecular integrity of the drug itself.
This platform doesn't treat diseases, it empowers treatment across diseases.
How It Works: From Molecule to Micro-Mist
Our system refines liquid medications into nano-emulsified formulations, which are then atomized by the Slyder Ultrasonic Nebulizer into an ultra-fine mist for deep pulmonary delivery. The result is a precise and consistent dose that can be administered repeatedly with minimal variability.
-
Improved drug solubility.
-
Enhanced cellular uptake
-
More effective target-site localization.
-
Reduced systemic side effects.
This approach is especially valuable for therapies that require high precision with low margin for error — from acute neurotherapies to pain interventions.
A Platform Technology, Not a Single Application
While nanoparticle delivery is being actively explored in oncology, its advantages extend far beyond cancer:
-
Neurological disorders (e.g., fast-acting treatments in seizure protocols).
-
Anxiety and pain relief where dosage control and onset time are critical.
-
Respiratory conditions requiring better penetration into affected regions.
-
Experimental formulations in pharma-sponsored clinical trials.
Why It Matters for Clinical Research and Institutions
Nanoparticle delivery is only as powerful as the system it runs on. That’s why IVPMED integrates:
-
A regulated, medical-grade devices (Slyder-nebulizer or).
-
A doctor-facing AI dashboard for dosing control & monitoring.
-
HIPAA-compliant, blockchain-secured data collection.
-
Support for multi-site clinical trials with centralized analytics.
Researchers and institutions gain access to real-time insight, while maintaining strict compliance with clinical standards.
bottom of page